Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus PROVERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus PROVERA.
ESTRADIOL AND NORETHINDRONE ACETATE vs PROVERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen that binds to estrogen receptors (ERα/ERβ) to regulate gene transcription involved in reproductive and non-reproductive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, inducing secretory endometrium and inhibiting gonadotropin secretion.
Provera (medroxyprogesterone acetate) is a progestin that binds to progesterone receptors, suppressing gonadotropin secretion, inhibiting endometrial growth, and inducing secretory changes in the endometrium. It also has antigonadotropic effects by reducing LH and FSH release from the pituitary.
1 tablet (estradiol 1 mg / norethindrone acetate 0.5 mg) orally once daily; adjust dose based on response and tolerability.
Oral: 5-10 mg daily for 5-10 days for secondary amenorrhea; 5-10 mg daily for 12-14 days per cycle in combination with estrogen for endometrial hyperplasia; 400-1000 mg/day IM monthly for endometriosis.
None Documented
None Documented
Estradiol: terminal ~12-14 hours; norethindrone acetate: terminal ~8-11 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life is approximately 12-17 hours for medroxyprogesterone acetate (oral). With depot intramuscular injection, the half-life is extended to approximately 50 days due to slow absorption from the injection site.
Estradiol: primarily renal as metabolites (glucuronide and sulfate conjugates), ~90% in urine, ~10% in feces as bile. Norethindrone: urinary (50-70% as metabolites) and fecal (20-30%).
Renal (50-60% as metabolites), biliary/fecal (30-40%). Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin